Galmed製藥 GLMD 深 滬
等待開盤 09-03 09:30:00 美东时间
1.27
0.000
0.00%
華盛通- 最 高1.3195
- 今 開1.26
- 成交量 8.36万股
- 最 低 1.24
- 昨 收 1.27
- 總市值 286.77万
- 52周最高 23.80
- 市盈率 靜 --
- 換手率 3.70%
- 52周最低 1.15
- 委 比 27.85%
- 總股本 225.80万
- 歷史最高 4870.80
- 量 比 0.17
- 振 幅 6.26%
- 歷史最低 1.15
- 每 手 1
- 風險率 1.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Galmed Pharmaceuticals Q2 EPS $(0.63) Beats $(0.83) Estimate
Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.83) by 24.1 percent. This is a 61.82 percent increase over losses of $(1.65) per share
08-28 21:36
Globus Medical, Inc. Secures Jury Verdict in Delaware Patent Litigation Against Life Spine, Inc.
Globus Medical, a leading musculoskeletal technology company, announced that a Delaware jury ruled in its favor in a patent infringement case against Life Spine, Inc. The jury found Life Spine's Prolift implants infringed Globus' valid patent and awarded both lost profits and reasonable royalty damages. The technology in question involves expandable spinal fusion implants, which improve patient outcomes in spinal surgery. Keith Pfeil, President a...
08-28 20:30
MASH drug developers rise as FDA accepts lenient trial requirement
Drug developers with products targeting a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Wednesday after the U.S. FDA said it has accepted an easy-to-m...
08-28 01:44
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Shares of Palo Alto Networks, Inc. (NASDAQ:PANW) rose sharply in pre-market tra...
08-19 20:01
Galmed Pharmaceuticals Reschedules Shareholder Meeting Due to Lack of Quorum
The latest update is out from Galmed Pharmaceuticals ( ($GLMD) ). On August 14,...
08-15 04:32
Galmed Pharma Announces Discovery Of Proprietary PD Blood-Based Biomarker Signature For Aramchol, Clinically Advanced Stearoyl-Coa Desaturase 1 Inhibitor
Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, unlocking potential new commercial and clinical pathways.Validated decrease in ANP
05-27 20:03
Galmed Pharmaceuticals Q1 EPS $(0.62) Beats $(0.89) Estimate
Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.89) by 30.34 percent. This is a 70.48 percent increase over losses of $(2.10) per share
05-22 20:13
Galmed GAAP EPS of -$0.62 beats by $0.27
Galmed press release (NASDAQ:GLMD): Q1 GAAP EPS of -$0.62 beats by $0.27. Cash and cash equivalents, short term deposits, restricted cash and marketable debt securities totaled approximately $15.9 mil...
05-22 20:06
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models
Aramchol, an SCD1 inhibitor, significantly attenuates and prevents biliary fibrosis in mouse models of primary sclerosing cholangitis (PSC) Aramchol treatment leads to significant inhibition...
05-13 20:00
Galmed Pharmaceuticals Signs Agreement for Novel Semaglutide Formulation
An announcement from Galmed Pharmaceuticals ( ($GLMD) ) is now available. On Ap...
04-28 20:53
